Ultrastructural and immunohistochemical analysis of rat uroepithelial cell junctions after partial bladder outlet obstruction and selective COX-2 inhibitor treatment.
The present study was undertaken to evaluate alterations in uroepithelial cell junctional complexes in partial bladder outlet obstruction (PBOO) of rat bladders using ultrastructural morphometry and immunohistochemistry, and to determine whether selective COX-2 inhibitors have any effects on these structures. A total of 18 male rats were separated into three groups of six rats each: (1) sham-operated animals served as controls; (2) a PBOO group, without further treatment (3) and a group that immediately after PBOO, received treatment for 4 weeks with oral Celecoxib, a selective COX-2 inhibitor. Uroepithelial cell junctions were evaluated using transmission electron microscopy combined with morphometry. Results were also assessed by E-cadherin and alpha-catenin immunohistochemistry. Morphometrical analysis of ultrastructural evaluations revealed that 4 weeks of PBOO caused a significant reduction in the electron density of zonula adherens and zonula occludens junctional complexes. Moreover, some desmosomes located between the deeper cells of the uroepithelium showed signs of disintegration. Selective COX-2 inhibitor treatment during 4 weeks of PBOO showed protective effects on adherens and occludens junctions, as well as on desmosomes. Immunohistochemical analysis of E-cadherin confirmed that the decreased E-cadherin immunolabelling in 4 weeks of PBOO was prevented by selective COX-2 inhibitor treatment. Based on ultrastructural morphometrical analysis, we conclude that PBOO alone and in combination with selective COX-2 inhibitors can have considerable effects on uroepithelial cellular junctions. Our findings provide a novel area of investigation regarding the selective use of COX-2 inhibitors following PBOO.
Celik-Ozenci
Ciler
C
Department of Histology and Embryology, Faculty of Medicine, Akdeniz University, Campus, 07070, Antalya, Turkey. cilercelik@yahoo.com
Ustunel
Ismail
I
Erdogru
Tibet
T
Seval
Yasemin
Y
Korgun
Emin Turkay
ET
Baykara
Mehmet
M
Demir
Ramazan
R
D022005:Adherens Junctions / Q000737:chemistry / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D000818:Animals; D015820:Cadherins / Q000032:analysis; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D003896:Desmosomes / Q000187:drug effects / Q000648:ultrastructure; D007150:Immunohistochemistry; D007365:Intercellular Junctions / Q000737:chemistry / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure*; D008297:Male; D046529:Microscopy, Electron, Transmission; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000494:pharmacology; D019108:Tight Junctions / Q000737:chemistry / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D001743:Urinary Bladder / Q000737:chemistry / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure*; D001748:Urinary Bladder Neck Obstruction / Q000378:metabolism / Q000473:pathology*; D019459:Urothelium / Q000737:chemistry / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure*; D051178:alpha Catenin / Q000032:analysis
D015820:Cadherins; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051178:alpha Catenin; D000068579:Celecoxib